Drug Safety

Top Research Topics at Drug Safety?

Adverse effect, Internal medicine, Pharmacology toxicology, Pharmacovigilance and Pharmacology are the subjects of interest in the journal. The studies in Adverse effect featured incorporate elements of Anesthesia, Clinical trial, Surgery and Intensive care medicine. Gastroenterology, Endocrinology, Oncology and Cardiology are some topics wherein Internal medicine research discussed in Drug Safety have an impact.

The Pharmacology toxicology study featured in it draws connections with the study of Drug reaction. Issues in Pharmacovigilance were discussed, taking into consideration concepts from other disciplines like MEDLINE, Adverse drug reaction, Family medicine, Medical emergency and Pediatrics. Drug Safety features Pediatrics research that overlaps with concepts in Medical prescription.

Pharmacology, which encompasses Drug and Drug interaction, is the main subject of the journal.

• Adverse effect (23.13%)
• Internal medicine (22.30%)
• Pharmacology toxicology (21.04%)

What are the most cited papers published in the journal?

• Under-reporting of adverse drug reactions : a systematic review. (1172 citations)
• H1-receptor antagonists. Comparative tolerability and safety. (878 citations)
• The medical dictionary for regulatory activities (MedDRA). (734 citations)

Research areas of the most cited articles at Drug Safety:

The published papers focus on Adverse effect, Internal medicine, Pharmacology, Drug and Intensive care medicine. The studies on Adverse effect discussed at the most cited publications can also contribute to research in the domains of Anesthesia, Clinical trial, Antibacterial agent and Immunology. Incidence (epidemiology), Surgery, Pharmacovigilance and MEDLINE are some topics wherein Intensive care medicine research discussed in the journal publications has an impact.

What topics the last edition of the journal is best known for?

• Internal medicine
• Disease
• Diabetes mellitus

The previous edition focused in particular on these issues:

Drug Safety focuses largely on the fields of MEDLINE, Pharmacovigilance, Internal medicine, Adverse effect and Pharmacology toxicology. Drug Safety facilitates discussions on MEDLINE that incorporate concepts from other fields like Health care, Agency (sociology), Emergency medicine, Intensive care medicine and Drug. While work presented in the journal provided substantial information on Pharmacovigilance, it also covered topics in Adverse drug reaction, Risk management, Process management and Medical emergency.

The journal focuses on Internal medicine research which is adjacent to topics in Oncology. In addition to Adverse effect research, it aims to explore topics under Clinical trial, Discontinuation, Incidence (epidemiology) and Anaphylaxis. The journal focuses on Pharmacology toxicology but the discussions also offer insight into other areas such as Health professionals, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus disease 2019 (COVID-19) and Knowledge management.

The most cited articles from the last journal are:

• Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review (8 citations)
• Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. (7 citations)
• PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. (6 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Drug Safety (based on the number of publications) are:

• Saad A. W. Shakir (72 papers) published 2 papers at the last edition, 1 less than at the previous edition,
• I. Ralph Edwards (56 papers) published 1 paper at the last edition,
• Nicholas Moore (42 papers) published 1 paper at the last edition, 2 less than at the previous edition,
• Eugène van Puijenbroek (39 papers) published 3 papers at the last edition, 2 less than at the previous edition,
• Peter G. M. Mol (38 papers) published 3 papers at the last edition, 1 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Drug Safety (based on the number of publications) are:

• Uppsala Monitoring Centre (132 papers) published 4 papers at the last edition, 8 less than at the previous edition,
• Utrecht University (72 papers) published 4 papers at the last edition, 3 more than at the previous edition,
• University of Groningen (67 papers) published 3 papers at the last edition, 2 less than at the previous edition,
• French Institute of Health and Medical Research (64 papers) published 7 papers at the last edition, 2 less than at the previous edition,
• Erasmus University Rotterdam (62 papers) published 3 papers at the last edition the same number as at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 7.44% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 29.46% were posted by at least one author from the top 10 institutions publishing in the journal. Another 11.61% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 25.89% of all publications and 33.04% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Role of Nursing in Drug Safety

Besides being heavily involved in pharmacovigilance, nursing professionals equally play an integral role in ensuring drug safety. Their role extends from the administration of drugs to monitoring their effects on patients, thus contributing significantly to the data used in the studies found within this journal. Importantly, nurses, particularly those dealing with special patient populations such as children and the elderly, must stay up-to-date with best practices in drug administration and monitor any adverse reactions that can occur. The synergy of medicine and nursing is a crucial aspect in achieving optimal patient care and promoting drug safety. To give an example, in their routine work, nurses usually manage medication delivery, identify drug reactions, and advocate for patient safety. They are also involved in implementing necessary steps in case of an adverse drug reaction. For those pursuing a career in the nursing field, and are interested in contributing towards the improvement of drug safety, there are several nursing programs available. For instance, the best online nursing programs in South Carolina offer comprehensive training that equips aspiring nurses with the knowledge and skills necessary for effective drug safety practice. Thus, the role of nursing in drug safety and pharmacovigilance cannot be overstated. Through their hands-on engagement with patients, their contribution to the safe use of drugs significantly impacts patient care outcomes.